Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study

Table 3 Unadjusted and adjusted model showing the association between days of use of sulfasalazine treatment and dementia diagnosis in people with rheumatoid arthritis using conditional logistic regression

Variable group	Model 0		Model 1		Model 2
Variable group	Unadjusted OR (95% CI)	p value	Adjusted OR (95% CI)	p value	Adjusted OR (95% CI)	p value
No sulfasalazine use	Ref		Ref		Ref
Sulfasalazine use for 0.49 years (first tertile)	0.60 (0.28–1.31)	0.20	0.65 (0.30–1.41)	0.28	0.65 (0.30–1.41)	0.28
Sulfasalazine use for 0.49 to 2.21 years (second tertile)	0.93 (0.45–1.93)	0.85	0.94 (0.45–1.95)	0.86	0.89 (0.43–1.85)	0.76
Sulfasalazine use for > 2.21 years (third tertile)	1.21 (0.58–2.51)	0.62	1.16 (0.55–2.44)	0.69	1.19 (0.57–2.48)	0.65

Model 0, no adjustment; model 1, adjustment for age, BMI, stroke and AMI; model 2, same as model 1 but not including stroke variable. OR odds ratio for dementia risk

ISSN: 1758-9193